Takashi Ninomiya
Shikoku Cancer Center · 145 works · 1,621 citations · h-index 22
Top works
- A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
- A framework for identification of actionable cancer genome dependencies in small cell lung cancer
- Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
- The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
- Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
- Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model
- Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
- Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
- Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)
- VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
- JAK 2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation
- Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E
- Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden
- Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study
- Ventricular Tachycardia and Takotsubo-like Syndrome in a Patient Undergoing Afatinib Treatment for Advanced Lung Adenocarcinoma
- Subpopulation of small‐cell lung cancer cells expressing CD 133 and CD 87 show resistance to chemotherapy
- MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
- Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
- A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
- Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model